FDA Approves Trastuzumab-pkrb for Treatment of HER2-Positive Breast Cancer

On December 14, Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. announced that the FDA has approved trastuzumab-pkrb (Herzuma), a biosimilar to Herceptin, for the treatment of HER2-positive breast cancer.

Read the Celltrion press release here.

Posted 12/17/2018